登录    
  
首页 > 期刊论文 > 论文摘要
STI 571增强非小细胞肺癌对顺铂的敏感性
         
STI 571 potentiates the sensitivity of non-small cell lung cancer cell line A549 to cytotoxic effects of cisplatin in vitro

摘    要
目的:比较STI 571单药及联合顺铂(DDP)对非小细胞肺癌(non-small cell lung cancer,NSCLC)细胞株A549及其DDP耐药株(A549/DDP)的增殖、细胞周期和凋亡的影响以及STI 571相关受体在NSCLC组织中的表达。方法:体外培养A549和A549/DDP细胞,应用MTT法测定STI 571和(或)DDP对细胞的增殖作用;通过FCM法分析细胞周期和凋亡;应用免疫细胞化学和免疫组织化学染色分别测定A549细胞株和NSCLC组织中STI 571相关受体的表达。根据Kaplan-Meier生存曲线,比较血小板衍化生长因子受体(platelet-derived growth factor receptor,PDGFR)-α和-β的表达与NSCLC患者总体生存的关系。结果:STI 571单药对A549/DDP细胞有增殖抑制作用,能增强细胞对DDP的敏感性,增加A549/DDP细胞的G2/M期和S期的细胞数,诱导其凋亡。STI 571在 < 10μmol/L时,对A549细胞增殖无明显影响。A549细胞和A549/DDP细胞均表达PDGFR-α和-β,后者还表达c-KIT蛋白。在肺腺癌中,PDGFR-α和PDGFR-β的表达率分别为65.5%和69.0%,与肺鳞癌的70.4%和74.1%相似,仅1例肺鳞癌表达c-KIT(3.7%)。表达PDGFR-α和-β的患者3年生存率和总体生存与不表达患者相似。结论:STI 571可以抑制DDP耐药的NSCLC细胞株的增殖,诱导其凋亡,并能增加DDP耐药细胞对DDP的敏感性。在NSCLC患者中,PDGFR-α和-β的表达水平与预后无关。
标    签 癌,非小细胞肺   抗药性,肿瘤   增生抑制作用   STI 571   顺铂   Carcinoma, non-small cell lung   Drug resistance, neoplasm   Proliferation inhibition   STI 571   Cisplatin  
 
Abstract
Objective: This study was designed to compare the effects of STI 571 on proliferation, cell phases, and apoptosis between A549 and cisplatin-resistant A549 cells(A549/DDP) and detect the expressions of STI 571-related receptors in non-small cell lung cancer(NSCLC) tissues.Methods: A549 and cisplatin-resistant A549 cells(A549/DDP) were cultured in vitro.The cell proliferation was measured by MTT assay.Cell cycle distribution and apoptosis induced by STI 571, cisplatin and their combination were detected by flow cytometry in NSCLC cell lines.The expressions of platelet-derived growth factor receptor(PDGFRs) -α and -β and c-KIT in the non-small cell lung cancer cell lines and tissues were investigated by immunocytochemistry and immunohistochemistry, respectively.Kaplan-Meier survival curves were used to compare the correlation of PDGFR-α and-β expression with total survival of NSCLC patients.Results: STI 571 inhibited proliferation of A549/DDP cells, sensitized them to cisplatin chemotherapy, increased the cell number in G2/M and S phase, and induced apoptosis.However, STI 571 at the concentration below 10 μmol/L had no effect on the proliferation of A549 cells.Both A549 and A549/DDP cells expressed PDGFR-α and-β, but c-KIT expression was only observed in A549/DDP cells.The expression rates of PDGFR-α and-β were 65.5% and 69% in pulmonary adenocarcinoma, similar to those in squamous carcinoma(70.4% and 74.1%).Only one case of squamous carcinoma expressed c-Kit(3.7%).The PDGFR-α or β-positive patients had similar 3-year survival rates and overall survival time with the PDGFRα or β-negative patients.Conclusion: STI 571 could suppress proliferation of A549/DDP cells, induce apoptosis and increase the sensitivity of A549/DDP to cisplatin.The levels of PDGFRα and β expression did not correlate with the prognosis of NSCLC patients.

中图分类号 R734.2 R73-36   DOI 10.3781/.jissn.1000-7431.2008.08.003

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 基础研究

基金项目

收稿日期 2007/12/12

修改稿日期 2008/3/18

网络出版日期

作者单位点击查看


备注周崧雯(1973-),女(汉族),硕士,讲师,主治医师

引用该论文: ZHOU Song-wen,ZHOU Cai-cun,SHU Chun-xia,ZHAO Ying-min,SU Bo. STI 571 potentiates the sensitivity of non-small cell lung cancer cell line A549 to cytotoxic effects of cisplatin in vitro[J]. Tumor, 2008, 28(8): 646~650
周崧雯,周彩存,苏春霞,赵印敏,粟波. STI 571增强非小细胞肺癌对顺铂的敏感性[J]. 肿瘤, 2008, 28(8): 646~650


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】ESTEBAN E, GONZALEZ DE, SANDE LFERNANDEZ Y, SANDE L, et al. Prospective randomised phase Ⅱ study of docetaxel versus paclitaxel administered weekly in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy[J].Ann Oncol, 2003, 14(11):1640-1647.
 
【2】CAPDEVILLE R, BUCHDUNGER E, ZIMMERMANN J, et al. Glivec(ST1571, imatinib), a rationally developed, targeted anticancer drug[J].Nat Rev Drug Discov, 2002, 1(07):493-502.
 
【3】罗锦辉, 唐建武. 肺腺癌中PDGF-β、PDGFR-α的表达及意义[J].临床与实验病理学杂志, 2005, 21(01):84-86.
 
【4】DI BACCO AM, cOTrER TG. p53 expression in K562 cells is associated with easpase-mediated cleavage of c-ABL and BCR-ABL protein k inases[J].Br J Haematol, 2002, 117(03):588-597.
 
【5】STEPHENSON J. Researchers buoyed by promise of targeted leukemia therapy[J].JAM A, 2000, 283(03):317-321.
 
【6】DRUKER B J, TALPAZ M, RESTA D J, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J].N Engl J Med, 2001, 344(14):1031-1037.
 
【7】APPERLEY J F, GARDEMBAS M, MELO J V, et al. Respense to imatinib mesylate in patients with chronic myeloprolifemtive diseases with rearrangements of the platelet-derived growth factor receptor beta[J].N Engl J Med, 2002, 347(07):481-487.
 
【8】COOLS J, DEANGELO D J, GOTLIB J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome[J].N Engl J Med, 2003, 348(03):1201-1214.
 
相关信息
   标题 相关频次
 吉非替尼耐药细胞株的筛选和基因谱表达研究
 10
 Ⅳ型胶原对耐顺铂人肺腺癌细胞化疗诱导凋亡的影响
 9
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 8
 表皮生长因子受体基因CA简单重复序列多态性与晚期小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂临床疗效间的关系
 8
 人肺腺癌细胞株A549和A549/DDP的比较蛋白质组学研究
 8
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 8
 血管内皮生长因子C过表达或抑制表达对人小细胞肺癌NCI-H446细胞生物学行为的影响
 7
 靶向肿瘤新生血管的顺磁性纳米脂质体在MRI诊断肺癌中的研究
 6
 干细胞标志CD90与人肺腺癌A549细胞顺铂耐药之间的关系
 6
 人肺腺癌吉非替尼耐药细胞株中微小RNA的表达谱
 6
 cRGD-氧化铁纳米粒的构建及应用于核磁共振成像诊断中的动物研究
 5
 靶向血管新生肽修饰的氧化铁纳米粒对荷瘤裸鼠磁热疗的研究
 5
 表皮生长因子受体信号通路与卵巢癌耐药细胞株SKOV3/DDP相关性的研究
 5
 细胞外基质在非小细胞肺癌中的表达及与新辅助化疗的关系
 5
 血管抑素联合顺铂治疗Lewis肺癌
 5
 一种靶向肿瘤新生血管的新型长循环纳米脂质体的制备
 5
 GRIM-19基因对肺腺癌耐药细胞株A549/DDP药物敏感性及相关基因表达的影响
 4
 H101溶瘤腺病毒联合长春瑞滨/顺铂一线治疗晚期非小细胞肺癌
 4
 Luffin-β靶向融合免疫毒素的构建、表达及对非小细胞肺癌的抑制作用
 4
 RNA干扰抑制Apollon表达联合川芎嗪可增强白血病细胞对化疗药物的敏感性
 4
 靶向肺癌的紫杉醇长循环脂质体抑瘤作用研究
 4
 长程多柔比星化疗富集乳腺肿瘤干细胞
 4
 初治晚期无症状脑转移非小细胞肺癌患者全脑放疗的时序探讨
 4
 单药培美曲塞二线治疗晚期非小细胞肺癌的疗效观察
 4
 厄洛替尼治疗晚期非小细胞肺癌的临床研究
 4
 恶性胸腔和腹腔积液中ERCC1和BRCA1 mRNA的表达水平与顺铂敏感性的关系
 4
 非小细胞肺癌组织中血管内皮生长因子表达与树突状细胞分布的关系
 4
 高海拔地区老年非小细胞肺癌患者接受全电视胸腔镜下肺叶切除的安全性和预后分析
 4
 核仁磷酸蛋白和c-Src在耐药肺腺癌细胞中的表达及其与化疗耐药之间的关系
 4
 华蟾素联合卡介菌多糖核酸或顺铂腔内注射治疗恶性胸腹腔积液
 4

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2